Dalla Pozza, E
How Patients Gain and How They Get Hurt 6.1 Clear Benefits Semaglutide can significantly reduce blood sugar, promote weight loss of 1015% or more of body weight in many patients, and lower the risk of heart and kidney complications in highrisk groups.[12][13][3] For many people with diabetes and obesity, that translates to fewer heart attacks, less disability, and potentially longer, healthier lives.[1][3] 6.2 Real Harms and Tradeoffs Affordability and access: At current prices, longterm semaglutide therapy is out of reach for most patients worldwide without strong insurance or publichealth support.[18][28] Crowding out budgets: When a single class of drugs consumes a big chunk of health budgets, other areasvaccines, primary care, older but useful drugscan get squeezed.[29][18] Evergreening delays generics: By keeping cheaper competitors out, evergreening keeps prices high for longer, meaning millions of patients either delay treatment or never start it.[14][19][22] Safety and hype cycles: Rapid, celebritydriven uptake can outpace longterm safety data, leaving regulators and courts to deal with adverseevent litigation years later, as seen in emerging lawsuits.[25][13] Key point: The same system that produces lifechanging drugs can also keep them scarce, expensive and unevenly distributed
These molecules are hypothesized to potentially play significant roles in cell growth, migration, and angiogenesis
PMID 16214343
BA1b promoted secretion of incretin via increased gene expression of VDAC1 Because BA1b acts on voltage-dependent calcium channels of the cell membrane, the effects of BA1b on the four calcium channels (Cacna1a, CaV1.2, CaV1.3, and VDAC1) in SIOs were investigated (Fig
